Sen. Ron Wyden and other Democrats claim Pfizer used a "colossal" scheme to avoid paying billions in U.S. taxes.

Addressing the calculation of patent term extensions (PTEs) under the Hatch-Waxman Act, the US Court of Appeals for the Federal Circuit affirmed ...

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

Reporting zero taxable profits in the U.S. in 2019, Pfizer (NYSE:PFE) carried out possibly the largest tax-avoidance scheme ...

The European Commission approves MRK's pneumococcal 21-valent conjugate vaccine, Capvaxive, for pneumococcal vaccination in ...

Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...

Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA ...

Ea Bridgeway Blue Chip ETF's valuation is attractive, with a P/E ratio 12.5% below the S&P 500, driven by its sector ...

Despite this potential, the stock has fallen by 25% in the past 12 months -- so is it a bargain buy right now? During the ...

Hengrui Pharma signs exclusive licensing agreement for its heart disease drug with Merck & Co.

Merck & Co. is flexing its dividend muscles with 14 years of consecutive growth and a yield that's juicier than a ripe ...

Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and ...